Patents by Inventor Kerry Chester

Kerry Chester has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED IMMUNE CELLS
    Publication number: 20230049025
    Abstract: The invention relates to an immune cell that is capable of antibody-dependent cellular cytotoxicity and which comprises a nucleic acid sequence encoding a secreted antigen binding protein. The invention also concerns a method of producing the immune cell and medical uses for the immune cell.
    Type: Application
    Filed: January 21, 2021
    Publication date: February 16, 2023
    Inventors: Jonathan Fisher, Kerry Chester, John Anderson, Enrique Miranda Rota
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20220096654
    Abstract: The present disclosure relates to novel pyrrolobenzodiazepine antibody-drug conjugates (PBD-ADCs) and therapeutic uses thereof.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 31, 2022
    Inventors: Patricius Hendrikus Cornelis van Berkel, Persis Amrolia, Kerry Chester, Jenny Yeung
  • MATERIALS AND METHODS RELATING TO MODIFYING THE BINDING OF ANTIBODIES
    Publication number: 20150291695
    Abstract: The invention relates to materials and methods for modifying the binding of antibodies, and more particularly to antibodies that are obtainable by inserting an amino acid sequence capable of binding to a target into a complementarity determining region of a parent antibody so that the antibody thus obtained is capable of binding to the target. The invention further relates to the uses of the antibodies for therapy, diagnosis or imaging, and to methods of producing the antibodies.
    Type: Application
    Filed: May 13, 2015
    Publication date: October 15, 2015
    Inventors: Kerry Chester, Heide Kogelberg, John F. Marshall
  • Rationally-designed anti-???6 integrin antibody MFEVP1 and variants thereof, method of making such antibody and the use thereof in treating and diagnosis of disease
    Patent number: 9050321
    Abstract: The present invention relates to antibodies that are obtained by inserting an amino acid sequence capable of binding to a target into the complementarity determining region (CDR) of a parent antibody. The antibody thus obtained has a new binding specificity. For example, the antibodies of the present invention are able to bind to the target, such as ?v?6 integrin, while retaining one or more of the useful properties of the parent antibody.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: June 9, 2015
    Assignee: Cancer Research Technology Limited
    Inventors: Kerry Chester, Heide Kogelberg, John F. Marshall
  • MATERIALS AND METHODS RELATING TO MODIFYING THE BINDING OF ANTIBODIES
    Publication number: 20110053254
    Abstract: The invention relates to materials and methods for modifying the binding of antibodies, and more particularly to antibodies that are obtainable by inserting an amino acid sequence capable of binding to a target into a complementarity determining region of a parent antibody so that the antibody thus obtained is capable of binding to the target. The invention further relates to the uses of the antibodies for therapy, diagnosis or imaging, and to methods of producing the antibodies.
    Type: Application
    Filed: September 26, 2008
    Publication date: March 3, 2011
    Inventors: Kerry Chester, John F. Marshall, Heide Kogelberg
  • Antibodies against tumor surface antigens
    Publication number: 20080003646
    Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.
    Type: Application
    Filed: May 29, 2007
    Publication date: January 3, 2008
    Applicants: Cancer Research Technology Limited, Massachusetts Institute of Technology
    Inventors: Richard Begent, Kerry Chester, Christilyn Graff, K. Wittrup
  • Antibodies against tumor surface antigens
    Publication number: 20050147614
    Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.
    Type: Application
    Filed: July 1, 2003
    Publication date: July 7, 2005
    Inventors: Richard Begent, Kerry Chester, Christilyn Graff, K. Wittrup
  • Modifided carboxypeptidase enzymes and their use
    Publication number: 20050059133
    Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.
    Type: Application
    Filed: October 2, 2003
    Publication date: March 17, 2005
    Applicant: Cancer Research Technology Limited
    Inventors: Richard Begent, Kerry Chester, Nigel Minton, Anthony Rees, Surinder Sharma, Daniel Spencer
  • Modified carboxypeptidase enzymes and their use
    Patent number: 6656718
    Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: December 2, 2003
    Assignee: Cancer Research Technology Limited
    Inventors: Richard H. J. Begent, Kerry Chester, Nigel P. Minton, Anthony R. Rees, Surinder K. Sharma, Daniel I. R. Spencer
  • Modifided carboxypeptidase enzymes and their use
    Publication number: 20020090709
    Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.
    Type: Application
    Filed: July 5, 2001
    Publication date: July 11, 2002
    Inventors: Richard H. J. Begent, Kerry Chester, Nigel P. Minton, Anthony R. Rees, Surinder K. Sharma, Daniel I. R. Spencer